While these gene-targeted therapies have been transformative for HER2+ breast cancer, other breast cancer subtypes do not necessarily present such a straightforward gene-targeted therapy opportunity due to heterogeneity and clonal evolution. This evidence concerns the gene ERBB2 and breast cancer.